As such, cilostazol induced a reduction in the total number of platelet EVs in PAD patients (Nomura et al., 2004), while atorvastatin modified specific platelet EVs subpopulations, reducing those positive for P-selectin, tissue factor and glycoprotein-IIIa (Mobarrez et al., 2011). This evidence concerns the gene F3 and peripheral arterial disease.